Roche Presents New Data on Vabysmo and Susvimo at ARVO 2026
New real-world data confirm Vabysmo's effectiveness in drying the retina for nAMD and DME, while Susvimo shows potential for sustained disease control.
Asset / Drug
Drug and asset intelligence for Vabysmo with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.